Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + gemcitabine vs gemcitabine + carboplatin in advanced non-small cell lung cancer
2005-001577-97Phase 2Completed
- Sponsor
- Gunnar Hillerdal
- Start
- Aug 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pemetrexed, gemcitabine and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Gunnar Hillerdal. Primary endpoint: Response rate. Started Aug 2005; status: completed.
02
Drugs
pemetrexedgemcitabinecarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-001577-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001577-97.